Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price53.43 USD
Fair value43.91
Ethical score70.0/100
Our investment reviews on this name
2026-07-02Read Markup54.23-1.5% to today
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Bruker Corporation holds its Markup at $53.43. The statistical read favours the sellers, held for 12 days.
As held on the ledger · 2026-09-11
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 12 days
Price at the screen
$53.43
Valuation
N/A trailing · 22.36 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.26
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
32.73%
Below 33%
Interest-bearing debt is just 32.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
13.52%
Below 49%
Money owed to the company is 13.5% of assets, under the 49% limit.
Pass
Revenue purity
0.43%
Below 5%
Only 0.4% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-11 screen. The gold marker is the market price at the same screen. The price runs 17.8% above the base estimate.
Third-party analyst targets: 13 covering, consensus Buy. The average target sits +12% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-11 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Lab tools giant priced well beyond its value
Labs across universities and pharma sites depend on precise spectrometers and imaging systems to push their experiments forward. Bruker supplies those instruments yet trades at a 38% premium to our fair value with revenue expanding just 3% and both profit margins and returns on equity sitting at zero. Forward earnings sit at 24 times with no economic moat visible, so the numbers give us no reason to step in.
The analyst crowd still leans buy with a $60 median target, but that optimism ignores the thin growth and absent profitability. Ethical screens clear without issue, yet valuation alone removes any investment case here.
Risks centre on execution in a competitive scientific equipment market where slow top-line growth can quickly turn into further margin pressure. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
BRKR trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-23Markup$51.27-12.0%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 12.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (13 analysts) rates it buy, with a mean price target of $49.
2026-07-23Markup$58.23+7.4%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 7.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (13 analysts) rates it buy, with a mean price target of $49.
2026-07-18Markup$54.23+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (13 analysts) rates it buy, with a mean price target of $49.
2026-07-03Markup$54.23+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markup$54.23Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
